There is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone (French Groupe Oncologie Radiothérapie Tête et Cou [GORTEC] 2000-01 trial [Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma]). The protocol that can best compare with RT alone after ICT is still to be determined.

BACKGROUNDOnycholysis occurs in approximately 30% of patients treated with docetaxel. The efficacy and safety of an Elasto‐Gel frozen sock (FS) was investigated for the prevention of docetaxel‐induced nail and skin toxicity of the feet.METHODSPatients receiving docetaxel at a dose of 70 to 100 mg/m2 every 3 weeks were eligible for this matched case‐control study. Each patient wore an FS for 90 minutes on the right foot. The unprotected left foot acted as control. Nail and skin toxicities were assessed using National Cancer Institute Common Toxicity Criteria (version 3) and compared using a 2‐sample Wilcoxon matched‐pairs rank test adjusted for tied values.RESULTSFifty consecutive patients were included between April 2005 and January 2007. Nail toxicity was significantly lower in the FS‐protected foot compared with the control foot (grade 0: 100% versus 79%; and grade 1 and 2: 0% versus 21%, respectively) (P = .002). Skin toxicity was grade 0: 98% versus 94%; and grade 1 and 2: 2% versus 6% in the FS‐protected and the control feet, respectively. The median times until toxicity occurrence were not found to differ significantly between the groups. One patient experienced discomfort because of cold intolerance.CONCLUSIONSCold therapy using FS significantly reduced the incidence of docetaxel‐induced foot nail toxicity, as previously demonstrated using frozen gloves for the hands. Cancer 2008. © 2008 American Cancer Society.

No abstract

No abstract

Background: Real-world data on cabozantinib in metastatic renal cell carcinoma (mRCC) is limited. This study (CABOREAL) reports treatment patterns and outcomes for patients treated with cabozantinib through the French Early Access Program. Patients and methods: This multicentre (n Z 26), observational, retrospective study enrolled patients with mRCC who had received 1 dose of cabozantinib. Overall survival (OS) was estimated using the KaplaneMeier method; subgroups were compared using the log-rank test.A multiple Cox regression model assessed predictive factors of OS after cabozantinib initiation. Results: Four hundred and ten recruited patients started treatment between September 2016 and February 2018: the Eastern Cooperative Oncology Group Performance Status 2, 39.3%; poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, 31.7%; 0e1, 2 and 3 previous treatment lines, 25.3%, 33.4% and 41.2%, respectively; bone metastases, 55.9%; brain metastases, 16.8%. Median (minemax) follow-up was 14.4 (0 e30) months. Overall, 57.0% of patients had a dose reduction, 15.6% an alternative dose schedule. The median average daily dose was 40.0 mg. Median (quartile [Q]1eQ3) treatment duration was 7.6 (0.1e29.1) months, median OS was 14.4 months, and the 12-month OS rate was 56.5% (95% confidence interval: 51.5e61.2). Most patients (54.4%) received subsequent treatment. Predictive factors associated with longer OS were body mass index 25 kg/m 2 (p Z 0.0021), prior nephrectomy (p Z 0.0109), favourable or intermediate IMDC risk (p < 0.0001) and cabozantinib initiation at 60 mg/day (p Z 0.0486). Conclusions: In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation at 60 mg/day was associated with improved outcomes. ClinicalTrials.gov identifier: NCT03744585.